| 1 |
35053324 | Raltegravir Inclusion Decreases CD4 T-Cells Intra-Cellular Viral Load and Increases CD4 and CD28 Positive T-Cells in Selected HIV Patients. | 2022 Jan 8 |
2 |
| 2 |
34288357 | Impact of switching to raltegravir and/or adding losartan in lymphoid tissue fibrosis and inflammation in people living with HIV. A randomized clinical trial. | 2021 Sep |
2 |
| 3 |
34784398 | Evaluation of several serum interleukins as markers for treatment effectiveness in naïve HIV infected patients: A pilot study. | 2021 |
1 |
| 4 |
32702281 | Impact of antiretroviral regimen on viral suppression among pregnant women living with HIV in Brazil. | 2020 Aug |
1 |
| 5 |
32941476 | A randomized pilot trial to evaluate the benefit of the concomitant use of atorvastatin and Raltegravir on immunological markers in protease-inhibitor-treated subjects living with HIV. | 2020 |
1 |
| 6 |
30625208 | Long-term tolerability and effectiveness of raltegravir in Japanese patients: Results from post-marketing surveillance. | 2019 |
1 |
| 7 |
31560700 | A prospective randomized trial on abacavir/lamivudine plus darunavir/ritonavir or raltegravir in HIV-positive drug-naïve patients with CD4<200 cells/uL (the PRADAR study). | 2019 |
1 |
| 8 |
29112076 | Virologic suppression and CD4+ cell count recovery after initiation of raltegravir or efavirenz-containing HIV treatment regimens. | 2018 Jan 14 |
1 |
| 9 |
27655859 | Different impact of raltegravir versus efavirenz on CD4/CD8 ratio recovery in HIV-infected patients. | 2017 Jan |
5 |
| 10 |
23412015 | Durable efficacy and safety of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naive HIV-1-infected patients: final 5-year results from STARTMRK. | 2013 May 1 |
2 |
| 11 |
23475910 | A case of possible darunavir/ritonavir-induced peripheral neuropathy: case description and review of the literature. | 2013 May-Jun |
1 |
| 12 |
23677919 | Early but limited effects of raltegravir intensification on CD4 T cell reconstitution in HIV-infected patients with an immunodiscordant response to antiretroviral therapy. | 2013 Oct |
4 |
| 13 |
23739328 | HIV-1 causes CD4 cell death through DNA-dependent protein kinase during viral integration. | 2013 Jun 20 |
1 |
| 14 |
24049167 | An HIV-1 replication pathway utilizing reverse transcription products that fail to integrate. | 2013 Dec |
1 |
| 15 |
21762404 | Safety and effectiveness of raltegravir in patients with haemophilia and anti-HIV multidrug resistance. | 2012 Jan |
1 |
| 16 |
22210634 | Mechanisms involved in CD4 cell gains in HIV-infected patients switched to raltegravir. | 2012 Mar 13 |
4 |
| 17 |
22820096 | Virological evidence supporting the use of raltegravir in HIV post-exposure prophylaxis regimens. | 2012 |
1 |
| 18 |
22948290 | A pilot study to assess inflammatory biomarker changes when raltegravir is added to a virologically suppressive HAART regimen in HIV-1-infected patients with limited immunological responses. | 2012 |
1 |
| 19 |
22992577 | The effect of intensification with raltegravir on the HIV-1 reservoir of latently infected memory CD4 T cells in suppressed patients. | 2012 Sep 24 |
1 |
| 20 |
23018435 | Raltegravir intensification shows differing effects on CD8 and CD4 T cells in HIV-infected HAART-suppressed individuals with poor CD4 T-cell recovery. | 2012 Nov 28 |
2 |
| 21 |
21628534 | Single mutations in HIV integrase confer high-level resistance to raltegravir in primary human macrophages. | 2011 Aug |
2 |
| 22 |
21921224 | Long-term treatment with raltegravir or efavirenz combined with tenofovir/emtricitabine for treatment-naive human immunodeficiency virus-1-infected patients: 156-week results from STARTMRK. | 2011 Oct |
1 |
| 23 |
20233398 | Response of a simian immunodeficiency virus (SIVmac251) to raltegravir: a basis for a new treatment for simian AIDS and an animal model for studying lentiviral persistence during antiretroviral therapy. | 2010 Mar 16 |
1 |
| 24 |
20329808 | Raltegravir: in treatment-naive patients with HIV-1 infection. | 2010 Mar 26 |
2 |
| 25 |
20404738 | Raltegravir versus Efavirenz regimens in treatment-naive HIV-1-infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analyses. | 2010 Sep |
1 |
| 26 |
20452889 | Raltegravir, tenofovir, and emtricitabine in an HIV-infected patient with HCV chronic hepatitis, NNRTI intolerance and protease inhibitors-induced severe liver toxicity. | 2010 Feb 26 |
1 |
| 27 |
20694070 | Raltegravir: The evidence of its therapeutic value in HIV-1 infection. | 2010 Jun 15 |
1 |
| 28 |
20711481 | The effect of raltegravir intensification on low-level residual viremia in HIV-infected patients on antiretroviral therapy: a randomized controlled trial. | 2010 Aug 10 |
1 |
| 29 |
19717396 | Raltegravir has no residual antiviral activity in vivo against HIV-1 with resistance-associated mutations to this drug. | 2009 Nov |
1 |